Home・Lista de Ações・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Abrir

SetorSaúde

66.23 1.85

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

63.88

Máximo

66.3

Indicadores-chave
By Trading Economics
Rendimento	1.6B 2.7B
Vendas	-1B 11B
P/E Médio do Setor	17.524 64.641
EPS	1.58
Rendimento de Dividendos	4.03
Margem de lucro	23.309
Funcionários	32,500
EBITDA	1.5B 3.7B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+0.57% upside

Dividendos
By Acuity
Rendimento de Dividendos Médio do Setor	4.03% 2.31%
Próximos Ganhos	29 de out. de 2026
Próxima data de ex-dividendo	2 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	9.8B 128B
Abertura anterior	64.38
Fecho anterior	66.23

Sentimento de Notícias

By Acuity

48%

52%

146 / 340 Ranking em Healthcare

Bristol-Myers Squibb Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

31 de jul. de 2026, 19:16 UTC

News

Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

30 de jul. de 2026, 22:51 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

29 de jul. de 2026, 23:36 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

28 de jul. de 2026, 20:06 UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

27 de jul. de 2026, 22:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news driving the decline amid mixed broader market performance.

24 de jul. de 2026, 17:56 UTC

Bristol-Myers Squibb Co shares are higher, maintaining a positive trajectory since Thursday's close. No specific news was identified to explain today's price action.

23 de jul. de 2026, 00:01 UTC

Bristol-Myers Squibb Co shares are modestly higher in after-market trading, recovering from an earlier dip and remaining above their 20-day moving average.

22 de jul. de 2026, 23:11 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, reaching a notable rise while remaining above the 20-day moving average.

21 de jul. de 2026, 23:36 UTC

Bristol-Myers Squibb Co. shares are near unchanged in after-market trading, remaining above their 20-day moving average amid a solid performance backdrop.

20 de jul. de 2026, 23:41 UTC

Bristol-Myers Squibb Co. shares are trading roughly flat in after-market hours, remaining effectively unchanged since Monday's close amid no specific news.

Comparação entre Pares

Variação de preço

Bristol-Myers Squibb Co. Previsão

Preço-alvo

By TipRanks

0.57% parte superior

Previsão para 12 meses

Média 65.84 USD 0.57%

Máximo 80 USD

Mínimo 40 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Bristol-Myers Squibb Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

20 ratings

Comprar

Manter

Vender

Com base em 20 analistas que deram avaliações de ações para Bristol-Myers Squibb Co. - Dist nos últimos 3 meses.

Sentimento

By Acuity

146 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.